



Improve Lives, Offer Hope

New Therapies for Cardiovascular & Neurological Diseases

Presentation to Annual General Meeting of Shareholders

James Bonnar
Chief Executive Officer

Sydney NSW
19 November 2020

ASX:NYR



Important Notice & Disclaimer

This presentation has been prepared by Nyrada Inc (NYR or the Company). It should not be considered as an offer or invitation to subscribe for, or purchase any shares in NYR, or as an inducement to purchase any shares in NYR. No agreement to subscribe for securities in NYR will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.

This presentation is not a prospectus, product disclosure document, or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licensed to, and does not provide, financial advice.

This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends' and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements do not guarantee of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.

Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.

Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

Nyrada Summary

Drug discoverer and early stage developer

Diverse product portfolio, significant therapeutic and commercial potential, near term milestones.

High calibre Board and Scientific Advisory Board, including highly connected industry and research experts in the US, Europe, Japan and Australia.



Well-funded to move programs into the clinic having raised \$8.5M at IPO, with \$5.2M cash in bank.

Commercial business model focused on maximising the value of early stage drug candidates.



Vision

We can improve lives and offer hope through innovation

-  Deliver a single, cost-competitive and convenient **cholesterol lowering** treatment so that anyone can achieve a safe cholesterol level (**reduce heart attack and stroke**)
-  Deliver the first-ever **treatment to prevent secondary brain injury** following stroke and **traumatic brain injury** (**reduce mortality and disability**)

Mission

Advance our drug candidates towards value inflection and commercialize early

Nyrada Programs and Strategy

Cholesterol lowering


Small molecule *PCSK9 inhibitor* to lower LDL-cholesterol that can be administered as a pill that can be combined with a statin

📌 Value inflection point in 2-3 years

Brain injury

Intravenous drug administered to patients admitted to hospital after sustaining a TBI or suffering a Stroke


📌 Value inflection points at 3 and 5 years



Why is Lowering LDL Cholesterol Important?

High LDL Cholesterol leading cause of cardiovascular disease

Cardiovascular disease responsible for 1 in 4 deaths



Statin Drugs




Low cost



Suboptimal efficacy

US\$19B

Statin sales in 2017



19.4 million

Unable to achieve
LDL-C target despite
taking statin therapy

27.4 million

US adults with elevated
LDL-C are taking a statin

Current PCSK9 Inhibitors



Effective and safe
Synergy with statins



Expensive US\$5,800 per year
Inconvenient (2-4 weekly injection)

US\$950M

Repatha & Praluent sales in 2019

PCSK9 → LDL receptor degradation

Fewer receptors → high LDL cholesterol

PCSK9 inhibitor → low LDL cholesterol

Statin + current PCSK9 inhibitor = expensive and inconvenient

Encouraging Results in Cholesterol Lowering



Equivalence demonstrated between Nyrada's NYX-PCSK9i and the two FDA approved monoclonal PCSK9 antibody drugs **Repatha™** (Amgen) and **Praluent™** (Sanofi/Regeneron)

	- Statin	+ Statin
	% LDLR retention	% LDLR retention
No drug	51%	64%
NYX-PCSK9i	89%	90%
Repatha™	84%	89%
Praluent™	78%	88%



Potential for NYX-PCSK9i to be used **alone or combined with a statin** in a **single-pill oral treatment**



NYX-PCSK9i shown in pharmacokinetic study to have good oral bioavailability, achieving blood levels in the therapeutic range

Strong progress towards value inflection point in 2-3 years

Improving Quality of Life for Brain Injury patients


Each year in the US:

- 2.8 million people sustain a traumatic brain injury (TBI)
- 800,000 suffer a stroke

Neurology / physical rehabilitation only existing therapies


- One drug class for stroke (Suitable for less than 15% of patients)
- No treatment exists for TBI

- High mortality
- Severe life-long disability
- High ongoing healthcare cost




Minutes

Initial injury size



Hours



Days


Final injury size

Nyrada Brain Injury Solution



Treatment for secondary brain injury following Stroke or TBI

- Prevent cell death
- Attenuate damaged brain volume
- Improve survivability, limit disability, improve quality of life



Brain Injury Program Continues to Advance


- Two drug candidates **achieved therapeutic levels** in a preclinical pharmacokinetic study
- Drug levels in the brain were assessed via a 6-hour continuous intravenous infusion (preferred route for moderate-severe TBI and Stroke)
- Candidates were **well-tolerated** with no adverse effects observed
- A further pharmacokinetic study will evaluate lead candidate NYX-1010 at higher dose levels for a longer duration

On track to reach value inflection points at 3 & 5 years



Preclinical Pharmacokinetic Rat Study

- Drug candidate NYX-1010 maintained at therapeutic levels in the brain in PK rat study (intravenous dosing)
- Demonstrates delivery via preferred route for patients suffering from stroke and moderate-severe TBI with desired PK profiles for clinical studies




FY20 Financials & Corporate Achievements

- Successful listing on the ASX and fully subscribed IPO raising \$8.5 million
- A\$1.075 million cash rebate from the Australian Federal Government's Research & Development (R&D) tax incentive program in relation to the 2019FY
- Strong cash position, with A\$5.2 million in cash as at 30 September 2020
- Nyrada major shareholder and biotech entrepreneur Dr Ian Dixon was appointed as Non-Executive Director to the Board

	FY20	FY19
Revenue and other income	\$1,125,414	\$505,697
R&D and employee expenses	\$2,742,992	\$2,439,343
Other expenses	\$1,951,765	\$1,658,151
Net loss before share based payment expense	\$3,569,343	\$3,591,797
Net loss	\$5,773,667	\$4,095,130
Net operating cash outflow	\$4,410,623	\$2,005,359
Cash and cash equivalents at the end of the year	\$5,146,169	\$1,102,397

Since April 2020 >60% of spend related to R&D activities



* The December 2019 and March 2020 quarters admin and corporate expenditure was higher due to the costs associated with successfully listing on the ASX.

Key Milestones and Anticipated Newsflow

Cholesterol Lowering Program

H2 2020	H1 2021	H2 2021	H1 2022
------------	------------	------------	------------

Clinical candidate selection:

- In vivo efficacy study of NYX-PCSK9i (Q4 2020)
- X-ray crystal structure study (Q1 2021)
- In vitro lead optimisation - ongoing
- Preclinical safety studies - 2021

Program to enter clinic:

Brain Injury Program

H2 2020	H1 2021	H2 2021	H1 2022
------------	------------	------------	------------

Clinical candidate selection:

- Pharmacokinetic study with NYX-1010 evaluating brain levels and tolerability of longer duration & higher dose (Q4 2020)
- In vivo efficacy study in TBI (Q1 2021)

Program to enter clinic:

Corporate

- Potential industry collaborations / non-dilutive funding: **ongoing**

Corporate Snapshot

Nyrada
inc



Neuroprotection Animation



Cholesterol-Lowering
Animation



Research Note

Market capitalisation
(as at 18 November 2020) **\$21M**

Share price
(as at 18 November 2020) **\$0.195**

CDIs free float **76,072,869**

CDIs 12 months escrow **205,000**

CDIs 24 months escrow **33,105,853**

Cash at bank (30 September 2020) **A\$5.2M**

ASX listing **January 16, 2020**

 [@nyrada_inc](https://twitter.com/nyrada_inc)

 [@nyrada_inc](https://www.linkedin.com/company/nyrada_inc)

www.nyrada.com